# An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

> **NCT06169579** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Shenzhen NewDEL Biotech, Co., Ltd** · enrollment: 96 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ND-003 tablets
- **DRUG:** ND-003 tablets
- **DRUG:** ND-003 tablets
- **DRUG:** ND-003 tablets
- **DRUG:** ND-003 tablets
- **DRUG:** ND-003 tablets
- **DRUG:** ND-003 tablets
- **DRUG:** ND-003 tablets

## Key facts

- **NCT ID:** NCT06169579
- **Lead sponsor:** Shenzhen NewDEL Biotech, Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-02-04
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2024-11-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06169579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06169579, "An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06169579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*